NCT02257216 is a NA clinical trial of Vayarin® in Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Enzymotec.

Who is sponsoring NCT02257216?

NCT02257216 is sponsored by Enzymotec.

What drugs are being tested in NCT02257216?

Interventions in NCT02257216: Vayarin®, Placebo.

What condition does NCT02257216 study?

NCT02257216 studies Attention Deficit Hyperactivity Disorder (ADHD).

Is NCT02257216 still recruiting?

NCT02257216 is currently completed. Last updated 10 April 2018.

Last reviewed 2018-04-10 · How we verify

NCT02257216

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Sequential Parallel, Double-Blind, Placebo- Controlled Medical Food Study for the Safety and Efficacy of Vayarin® in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Completed NA Last updated 10 April 2018

What this trial tests

NA trial testing Vayarin® in Attention Deficit Hyperactivity Disorder (ADHD) in 171 participants. Completed in 1 June 2017.

Timeline

1 October 2014

Primary endpoint
1 May 2017

1 June 2017

Quick facts

Lead sponsor	Enzymotec
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	other
Enrollment	171
Start date	1 October 2014
Primary completion	1 May 2017
Estimated completion	1 June 2017
Sites	4 locations across United States

Drugs / interventions tested

Vayarin®
Placebo

Conditions studied

Attention Deficit Hyperactivity Disorder (ADHD) — all drugs for Attention Deficit Hyperactivity Disorder (ADHD) →

Sponsor

Enzymotec

Who can join

Adults 18 to 60, any sex, with Attention Deficit Hyperactivity Disorder (ADHD). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Adult ADHD Investigator Symptom Rating Scale (AISRS) total score
Time frame: over 16 weeks

Sponsor's own description

The primary study objective is to evaluate the efficacy of Vayarin in ADHD adults.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Attention Deficit Hyperactivity Disorder (ADHD)

Currently open trials in the same condition.

NCT06853665 — The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine · Phase 4 · recruiting
NCT07189442 — L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD · NA · recruiting
NCT06960980 — Improving ADHD Teen Driving - Virtual Reality · NA · recruiting
NCT06810180 — Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Het · NA · recruiting
NCT06885060 — Exploring Eye Vergence Markers ADHD) and ASD · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02257216 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Enzymotec
Last refreshed: 10 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02257216.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing